Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 SCHELLING CERTIFICATION PURSUANT TO SEC 906 - Acer Therapeutics Inc. | acer-ex321_8.htm |
| 10-K - 10-K - Acer Therapeutics Inc. | acer-10k_20191231.htm |
| EX-32.2 - EX-32.2 PALMIN CERTIFICATION PURSUANT TO SEC 906 - Acer Therapeutics Inc. | acer-ex322_12.htm |
| EX-31.2 - EX-31.2 PALMIN CERTIFICATION PURSUANT TO SEC 302 - Acer Therapeutics Inc. | acer-ex312_10.htm |
| EX-31.1 - EX-31.1 SCHELLING CERTIFICATION PURSUANT TO SEC 302 - Acer Therapeutics Inc. | acer-ex311_6.htm |
| EX-23.1 - EX-23.1 - Acer Therapeutics Inc. | acer-ex231_16.htm |
| EX-10.27 - EX-10.27 - Acer Therapeutics Inc. | acer-ex1027_794.htm |
| EX-4.1 - EX-4.1 - Acer Therapeutics Inc. | acer-ex41_179.htm |
EXHIBIT 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statements on Form S-3 (File No. 333-228319) and Form S-8 (File Nos. 333-230133, 333-221566, and 333-224942) of our report dated March 7, 2019 relating to the consolidated financial statements of Acer Therapeutics Inc., appearing in the Annual Report on Form 10-K of Acer Therapeutics Inc. for the year ended December 31, 2019.
We also consent to the references to us under the heading “Experts” in such Registration Statements.
/s/ Wolf & Company, P.C.
Wolf & Company, P.C.
Boston, Massachusetts
March 18, 2020